Efficacy of long-term prednisone therapy in patients with chronic inflammatory demyelinating polyneuropathy (CIDP): a retrospective cohort study

被引:1
|
作者
Lopez-Hernandez, Juan C. [1 ,2 ]
Mercado-Pompa, Andres [2 ]
Perez-Torres, Teresa [1 ,2 ]
Galnares-Olalde, Javier A. [1 ,2 ]
Vargas-Canas, Edwin S. [1 ,2 ]
机构
[1] Inst Nacl Neurol & Neurocirug, Dept Enfermedades Neuromusculares, Ciudad De Mexico, Mexico
[2] Inst Nacl Neurol & Neurocirug, Dept Neurol, Ciudad De Mexico, Mexico
关键词
Chronic; CIDP; Neuropathy; Prednisone; Prognosis; Treatment; DIAGNOSIS; NEUROPATHIES; REMISSION; PROGNOSIS;
D O I
10.33588/rn.7308.2021261
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction. Patients with CIDP respond adequately to steroid therapy and intravenous immunoglobulin (IVIG). However, few patients have access to IVIG in developing countries. little information exists about the clinical response to steroid therapy in Latin American countries. Objective. to describe the long-term functional clinical response (24 months) to prednisone therapy in CIDP patients. Material and methods. A retrospective cohort was conducted. Selection included patients with definitive CIDP diagnosis according to European criteria from the Neuromuscular Diseases clinic of the National Institute of Neurology and Neurosurgery between January 2016 and December 2020. Good response to steroid therapy was defined as with improvement in at least one point on the GBS disability score. Poor response to steroid therapy was defined as patients who did not show improvement in at least one point on the GBS disability score. Patients were evaluated at 3, 6, 12, 18 and 24 months. Results. Forty-seven patients with CIDP were included. Half of them were male and mean age was 46 +/- 15 years. Mean time since symptom onset to diagnosis was 6 (IQR 2-12) months. The most common clinical variant was sensory-motor 57.4%, followed by acute-onset CIDP 21.3% and atypical variants 21.2%. At diagnosis our patients presented: mean GBS disability score of 3 (2.25-4) points, MRC score 39.5 +/- 12 points, independent gait in 17%, mean prednisone dose of 50 mg (32.5-50). Twenty-four months after prednisone therapy, a less mean GBS disability score -1(0-2) points-, mean MRC score 56.3 +/- 5.1 points, independent gait 93% and prednisone dose 1 (0-5) mg. Patients with poor three-month functional clinical response had a delay in diagnosis > 6 months (64.7% vs 27.5%) and atypical clinical variants (47% vs 6.8%). Conclusion. CIDP patients treated with prednisone have good long-term functional clinical response. Delay in diagnosis and atypical variant are common clinical characteristics for poor functional clinical response in treatment with prednisone.
引用
收藏
页码:275 / 281
页数:7
相关论文
共 50 条
  • [21] A cross-sectional study of neuromuscular ultrasound in patients with chronic inflammatory demyelinating polyneuropathy (CIDP)
    Crump, Nicholas
    Cartwright, Michael
    MacDonell, Richard
    [J]. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2020, 25 (04) : 558 - 559
  • [22] GADOLINIUM ENHANCEMENT OF MRI SIGNAL IN PATIENTS WITH CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP)
    VO, DT
    BERTORINI, T
    LAWRENCE, J
    HALFORD, H
    WASSEF, M
    [J]. NEUROLOGY, 1993, 43 (04) : A247 - A247
  • [23] Cognitive impairment in patients with chronic inflammatory demyelinating polyneuropathy (Cidp) - preliminary report
    Slotwinski, K.
    Koszewicz, M.
    Dziadkowiak, E.
    Bladowska, J.
    Budrewicz, S.
    Podemski, R.
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2015, 357 : E345 - E346
  • [24] Comparison of electrodiagnostic criteria for demyelination in patients with chronic inflammatory demyelinating polyneuropathy (CIDP)
    Delmar S. M. Molenaar
    Marinus Vermeulen
    Rob J. de Haan
    [J]. Journal of Neurology, 2002, 249 : 400 - 403
  • [25] IVIG regulates BAFF expression in patients with chronic inflammatory demyelinating polyneuropathy (CIDP)
    Ritter, Christian
    Foerster, Dominik
    Albrecht, Philipp
    Hartung, Hans-Peter
    Kieseier, Bernd C.
    Lehmann, Helmar C.
    [J]. JOURNAL OF NEUROIMMUNOLOGY, 2014, 274 (1-2) : 225 - 229
  • [26] Comparison of electrodiagnostic criteria for demyelination in patients with chronic inflammatory demyelinating polyneuropathy (CIDP)
    Molenaar, DSM
    Vermeulen, M
    de Haan, RJ
    [J]. JOURNAL OF NEUROLOGY, 2002, 249 (04) : 400 - 403
  • [27] A population-based study of long-term outcome in treated chronic inflammatory demyelinating polyneuropathy
    Al-Zuhairy, Ali
    Sindrup, Soren H.
    Andersen, Henning
    Jakobsen, Johannes
    [J]. MUSCLE & NERVE, 2020, 61 (03) : 316 - 324
  • [28] Childhood chronic inflammatory demyelinating polyneuropathy: clinical course and long-term outcome
    Ryan, MM
    Grattan-Smith, PJ
    Procopis, PG
    Morgan, G
    Ouvrier, RA
    [J]. NEUROMUSCULAR DISORDERS, 2000, 10 (06) : 398 - 406
  • [29] Long-term regular plasmapheresis as a maintenance treatment for chronic inflammatory demyelinating polyneuropathy
    Isose, Sagiri
    Mori, Masahiro
    Misawa, Sonoko
    Shibuya, Kazumoto
    Kuwabara, Satoshi
    [J]. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2010, 15 (02) : 147 - 149
  • [30] Real-world data on the management of patients with multifocal motor neuropathy (MMN) or chronic inflammatory demyelinating polyneuropathy (CIDP) with immunoglobulins: long-term data of the SIGNS study
    Stangel
    Gold
    Baumann
    Borte
    Fashauer
    Hensel
    Huscher
    Pittrow
    Reiser
    Zessack
    Sommer
    [J]. SWISS MEDICAL WEEKLY, 2016, 146 : 95S - 95S